These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28458650)

  • 1. Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.
    Kiiski H; Jalkanen V; Ala-Peijari M; Hämäläinen M; Moilanen E; Peltola J; Tenhunen J
    Front Neurol; 2017; 8():144. PubMed ID: 28458650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study.
    Schmidt TP; Albanna W; Weiss M; Veldeman M; Conzen C; Nikoubashman O; Blume C; Kluger DS; Clusmann H; Loosen SH; Schubert GA
    Front Neurol; 2022; 13():841024. PubMed ID: 35359651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasma UCH-L1 after aneurysmal subarachnoid hemorrhage is associated with unfavorable neurological outcome.
    Kiiski H; Tenhunen J; Ala-Peijari M; Huhtala H; Hämäläinen M; Långsjö J; Moilanen E; Narkilahti S; Öhman J; Peltola J
    J Neurol Sci; 2016 Feb; 361():144-9. PubMed ID: 26810533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100B, NSE and MMP-9 fail to predict neurologic outcome while elevated S100B associates with milder initial clinical presentation after aneurysmal subarachnoid hemorrhage.
    Kiiski H; Långsjö J; Tenhunen J; Ala-Peijari M; Huhtala H; Hämäläinen M; Moilanen E; Peltola J
    J Neurol Sci; 2018 Jul; 390():129-134. PubMed ID: 29801873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
    Donadello K; Scolletta S; Taccone FS; Covajes C; Santonocito C; Cortes DO; Grazulyte D; Gottin L; Vincent JL
    J Crit Care; 2014 Feb; 29(1):144-9. PubMed ID: 24120089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-courses of plasma IL-6 and HMGB-1 reflect initial severity of clinical presentation but do not predict poor neurologic outcome following subarachnoid hemorrhage.
    Kiiski H; Långsjö J; Tenhunen J; Ala-Peijari M; Huhtala H; Hämäläinen M; Moilanen E; Öhman J; Peltola J
    eNeurologicalSci; 2017 Mar; 6():55-62. PubMed ID: 29260012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
    Roelz R; Schubach F; Coenen VA; Jenkner C; Scheiwe C; Grauvogel J; Niesen WD; Urbach H; Taschner C; Seufert J; Kätzler J; Beck J; Reinacher PC
    Trials; 2021 Apr; 22(1):285. PubMed ID: 33858493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke.
    Różański D; Szlufik S; Tomasiuk R; Milanowski Ł; Figura M; Saramak K; Myrcha P; Koziorowski D
    Brain Sci; 2021 Dec; 12(1):. PubMed ID: 35053782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.
    Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P
    J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
    Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
    Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
    El-Mekkawy MS; Saleh NY; Sonbol AA
    Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Eur J Intern Med; 2019 Jun; 64():72-75. PubMed ID: 31060962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?
    Sunnetcioglu A; Sunnetcioglu M; Adıyaman F; Binici I; Soyoral L
    Clin Respir J; 2017 Nov; 11(6):925-930. PubMed ID: 26683264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between endothelin polymorphisms and aneurysmal subarachnoid hemorrhage, clinical vasospasm, delayed cerebral ischemia, and functional outcome.
    Griessenauer CJ; Starke RM; Foreman PM; Hendrix P; Harrigan MR; Fisher WS; Vyas NA; Lipsky RH; Lin M; Walters BC; Pittet JF; Mathru M
    J Neurosurg; 2018 May; 128(5):1311-1317. PubMed ID: 28548598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis.
    Vassiliou AG; Zacharis A; Vrettou CS; Keskinidou C; Jahaj E; Mastora Z; Orfanos SE; Dimopoulou I; Kotanidou A
    Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
    Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
    Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.